Genentech, Inc.

F. Hoffmann-la Roche Ag

Marian C Bryan

Naomi S Rajapaksa

James Richard Kiefer, Jr

Joy Drobnick

Jun Liang

Alberto Gobbi

Tamiko Katsumoto

Bryan K Chan

Eileen Mary Seward

Robert Andrew Heald

Steven Huy Do

Aleksandr Kolesnikov

Timothy Heffron

Mark Edward Zak

Emily J Hanan

Michael Lainchbury

Yun-Xing Cheng

Liqiang Fu

Jessica Grandner

Daniel G M Shore

Fei Wang

Alan G Olivero

F Anthony Romero

Jianwen A Feng

Chudi Obioma Ndubaku

Richard Leonard Elliott

Kwong Wah Lai

Jennafer Dotson

Zhiguo Liu

John Wai

Yongsheng Chen

Hans Purkey

Jamie Knight

Francois Diederich

Naomi Rajapaksa

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof, that are useful as JAK kinase inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases

Compounds of formula (I) wherein R, R, R, R, Rand Rare as defined herein, and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.

Pyrazolopyrimidine inhibitors of JAK kinases and uses thereof

Compounds of Formula I and methods of use as Interleukin-1 Receptor Associated Kinase 4 (IRAK4) inhibitors are described herein.

Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators

Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

Compounds of Formula 0, and stereoisomers and pharmaceutically acceptable salts thereof, as well as methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.

IRAK4 modulators

This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

Azaindazole compounds as inhibitors of T790M containing EGFR mutants

Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants

Growing community of inventors

South San Francisco, CA, United States of America

Marian C Bryan